(July 7, 2020) Presented as part of the American Association for Cancer Research (AACR) Virtual Annual Meeting, Dr. Kala Visvanathan and colleagues at Johns Hopkins found that statins “were associated with reduced mortality in patients with ovarian cancer.”
Statins are commonly prescribed as a treatment for high cholesterol. Participants in this study who used statins showed a 40 percent reduction in ovarian cancer mortality compared to patients who never took statins. Those patients who took lipophilic statins, specifically, were found to have a 43 percent reduction in mortality from ovarian cancer.
“Our results provide further evidence in support of the clinical evaluation of lipophilic statins as part of the treatment of ovarian cancer. These drugs are appealing as they are widely used, inexpensive, and well tolerated in most patients. The associated reduction in ovarian cancer mortality is promising,” Visvanathan was quoted by AACR.
For more, check out the news release from the American Association for Cancer Research (AACR), and coverage from HealthDay.